Trial intelligence / Profile preview

Icotinib vs epitinib in first-line EGFR-mutant NSCLC with brain metastases

CTR20160660Phase 3Suspended

Sponsor
HUTCHMED
Start
Jan 2018
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 3 trial of epitinib in non-small cell lung cancer (NSCLC), sponsored by HUTCHMED. Started Jan 2018; status: suspended.

02

Drugs

epitinib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on CTR20160660.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20160660.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call